𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma

✍ Scribed by Sophie D. Fossåu; Stephen T. De Garis; Mona S. Heier; Asbjøsrn Flokkmann; Hans H. Lien; Aud Salveson; Brit Moe

Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
552 KB
Volume
57
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Further experience with recombinant inte
Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: A progress report
✍ S. D. Fosså; S. T. De Garis 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 404 KB

Thirty-three patients with measurable metastatic renal cell carcinoma were entered into 2 consecutive phase II protocols using interferon alfa-2a. In protocol I, 20 patients were treated with interferon alfa-2a at a dose of 36 x I06 IU i.m. t.i.w. Vinblastine was also given t o 18 of these patients

Interferon-alpha antibodies in patients
Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial
✍ Otto Prümmer; Delta-P Study Group 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 657 KB

Background. Prolonged therapy with interferon (IFN) may lead to the formation of IFN antibodies. Methods. Patients with renal cell carcinoma (n = 270) with advanced localized disease were randomized after complete tumor resection to receive treatment with adjuvant recombinant IFN-alpha-2a (rIFN-a2a

Recombinant interferon α-2A combined wit
Recombinant interferon α-2A combined with prednisone in metastatic renal-cell carcinoma: Treatment results, serum interferon levels and the development of antibodies
✍ Sophie D. Fosså; Gustav Lehne; Ragnhild Gunderson; Unni Hielmaas; Eduard E. Hold 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 375 KB 👁 1 views

Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-a 2a (IFN) + prednisone (P). Four of 24 subsequent patients responded to IFN + P (combined response rate 19%). The median response duration was 8 months (3 to 30 months). The one-year sur